The pharma market gears up for weight-loss wonder drugs | DW News

Key Concepts:

• GLP-1s (Glucagon-like peptide-1s): A class of drugs revolutionizing weight loss treatment.
• Orforglipron: Eli Lilly's late-stage trial drug, an oral GLP-1 receptor agonist.
• Branded vs. Generic Drugs: Branded drugs are patent-protected, while generics are off-patent versions.
• Tariffs: Taxes imposed on imported goods, potentially impacting the pharmaceutical industry.
• Medicine Shortages: A potential consequence of high tariffs on generic drugs.
• Stockpiling: Accumulating excess inventory in anticipation of tariffs or other disruptions.
• National Institutes of Health (NIH): A primary source of funding for medical research in the US.

1. GLP-1 Weight Loss Drugs and Market Growth

• Market Size and Potential: The current market size for weight loss drugs is $30 billion, with potential growth to over $100 billion annually due to the prevalence of overweight individuals.
• Orforglipron Results: Eli Lilly's Orforglipron pill showed a 12.4% weight loss in late-stage trials, slightly below the forecasted 14%, but still significant.
• Accessibility: The introduction of a pill form makes GLP-1 drugs more accessible to a wider population, overcoming the barrier of injectables.
• Global Sales Projections: Global GLP-1 sales in 2023 were $40 billion, with estimates projecting growth to $150 billion by 2032.
• Societal Impact: Overweight and obesity are significant problems worldwide, with over 50% of the adult population in Germany and two-thirds in the US being overweight, leading to substantial economic costs.
• Growth Factors: The significant problem of obesity spurs growth.
• Hindering Factors: Factors hindering growth include insurance coverage limitations and a worldwide shortage of semaglutide, an active ingredient in some weight loss drugs.
• Pill Advantages: A pill form circumvents the aversion to needles and eliminates the need for refrigerated transport, making it more convenient for users.

2. Tariffs and the Pharmaceutical Industry

• Tariff Rates: The US has imposed varying tariff rates on different countries, such as 15% on the EU and 39% on Switzerland.
• Uncertainty: Tariffs create uncertainty for the pharmaceutical sector, especially with potential increases to 150-250% as suggested by the Trump administration.
• US Market Importance: The US is the most important pharmaceutical market, accounting for roughly 44% of global sales with only 5% of the population.
• Branded vs. Generic Impact: The threat of tariffs has incentivized branded manufacturers to invest in the US, while the impact on generic drug production is different.
• Vulnerable Countries: While the tariff is ultimately borne by US importers and consumers, countries like India, a major generic drug production hub, are vulnerable.
• Medicine Shortages and Price Rises: High tariffs could lead to medicine shortages, particularly in the generic drug sector, and price increases for consumers.
• Generic Drug Dependence: Over 90% of US prescriptions are for generic drugs, highlighting the strategic dependence on overseas manufacturers.
• Investment in Branded Manufacturing: There's an estimated $250 billion in investment by branded manufacturers in the US in response to tariffs.
• European Exposure: European manufacturing, particularly in Ireland, is exposed to US tariffs due to significant pharmaceutical production for the US market. Other exposed countries include Germany, the Netherlands, the United Kingdom and Switzerland.
• Stockpiling Effect: Pharmaceutical companies have been stockpiling products in the US in anticipation of tariffs, delaying the inflationary effect on prices.
• Gradual Price Increases: As stockpiles run out, gradual price increases for imported medication are expected, impacting consumers through over-the-counter purchases and healthcare insurance premiums.

3. Impact of NIH Funding Cuts on Pharmaceutical Innovation

• NIH Research Importance: Research funded by the National Institutes of Health (NIH), including studies on angler fish, has been fundamental to the development of innovative drugs like GLP-1s.
• Funding Cuts: Cuts of at least $1.8 billion to NIH grants by the Trump administration raise concerns about the future of pharmaceutical innovation in the US.
• Threat to Innovation: Cutting funding for high-risk research projects threatens the future innovative capacity of the pharmaceutical sector.
• China's Rising Influence: China is increasing its presence in pharmaceutical innovation, with the percentage of new molecules originating from Chinese biotech companies rising from 4% to 24% between 2014 and 2024.
• Potential Shift in Leadership: The next blockbuster drug may originate from China rather than the US due to these trends.

4. Notable Quotes

• "Even the mere threat of tariffs has incentivized branded manufacturers to invest in the US."
• "Over 90% of US prescriptions are a generic drug."
• "These cuts threaten the future innovative capacity of the sector."

5. Technical Terms and Concepts

• GLP-1s (Glucagon-like peptide-1s): A class of incretin mimetic drugs used to treat type 2 diabetes and obesity. They work by stimulating insulin release, suppressing glucagon secretion, and slowing gastric emptying.
• Semaglutide: An active ingredient in some GLP-1 weight loss drugs, facing worldwide shortages.
• Tariffs: Taxes imposed on imported goods.
• Branded Drugs: Pharmaceutical drugs that are protected by patents, giving the manufacturer exclusive rights to produce and sell the drug.
• Generic Drugs: Pharmaceutical drugs that are no longer protected by patents and can be produced and sold by multiple manufacturers.
• Stockpiling: The accumulation of excess inventory to mitigate potential supply disruptions or price increases.

6. Synthesis/Conclusion

The pharmaceutical industry is experiencing significant growth driven by GLP-1 weight loss drugs, with the potential for further expansion through oral formulations. However, factors like insurance coverage and drug shortages could hinder this growth. US tariffs pose a threat to the pharmaceutical industry, potentially leading to medicine shortages and price increases, particularly in the generic drug sector. While branded manufacturers are investing in the US in response to tariffs, the dependence on overseas generic drug production remains a vulnerability. Furthermore, cuts to NIH funding raise concerns about the future of pharmaceutical innovation in the US, potentially leading to a shift in global leadership towards countries like China.